Skip to main content

Menu

BNF for Children April 2022 Update

This update contains 8 significant changes, 3 dose changes, 1 new preparation, and 1 deleted preparation.

Significant Changes:

  • Chlorhexidine [primary therapeutic area changed to genito-urinary system, secondary therapeutic area changed to oropharynx].
  • Chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions [MHRA/CHM advice].
  • COVID-19 vaccines: updated guidance in-line with UK Health Security Agency recommendations.
  • Hydroxychloroquine sulfate: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions [MHRA/CHM advice].
  • Immunisation schedule: updated guidance in-line with UK Health Security Agency recommendations.
  • Ivacaftor: Ivacaftor, tezacaftor, elexacaftor (Kaftrio®▼) in combination with ivacaftor (Kalydeco®): risk of serious liver injury; updated advice on liver function testing [MHRA/CHM advice].
  • Remdesivir: reporting to the UK COVID-19 Antivirals Pregnancy Registry [MHRA/CHM advice].
  • Smoking cessation: updated guidance on management.

Dose Changes:

  • Eltrombopag [addition of Southeast Asian ethnicity to dosing for treatment of chronic idiopathic thrombocytopenic purpura].
  • Etanercept [update to dosing].
  • Hepatitis B immunoglobulin [update to dosing in prophylaxis against hepatitis B infection from birth to 4 years old, and dosing in prevention of transmitted infection at birth].

New Preparation:

  • Vaxelis® [diphtheria with tetanus, pertussis, hepatitis B, poliomyelitis and haemophilus influenzae type b vaccine]

Deleted Preparation:

  • Synflorix® [pneumococcal polysaccharide conjugate vaccine (adsorbed)]

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes